Life Sciences Marketing Is Losing Deals It Should Win. The Product Is Not the Problem.

Life sciences companies that lead on scientific innovation but trail on commercial storytelling are handing market share to competitors who can explain value faster. That gap — between what a product does and what a buying committee believes it can do — is now the primary determinant of win rates in complex therapeutic and instrumentation markets.

How should VP Marketing leaders close the product communication gap in life sciences sales?

According to Alexander Group, life sciences growth is splitting sharply: pharma and biotech teams see 6.3% actual growth, while analytical instruments and pharma services average just 1.2%. The separating variable is not product superiority — it is commercial model precision. Buyers in the slow lane are choosing vendors who explain value more clearly.

According to Forrester, “Customers don’t want products or services — they need to solve business problems.” This is the exact tension in life sciences marketing: teams default to feature enumeration when buyers are searching for outcome validation. A clinical workflow story told wrong becomes a spec sheet. Told right, it becomes the reason a procurement committee moves forward without three more review cycles.

The companies gaining share in 2026 are not the ones with the most sophisticated science — they are the ones whose marketing makes that science comprehensible to a buying committee of eight. Kaon builds the interactive communication environments that let VP Marketing teams translate complex clinical and operational value into buyer-ready experiences that work at scale, across channels, and without a PhD in the room.